Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 12—December 2022
Research

Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali

Léa LucianiComments to Author , Nathanaël Lapidus, Abdennour Amroun, Alessandra Falchi, Chanthala Souksakhone, Mayfong Mayxay, Audrey Dubot-Pérès, Paola Mariela Saba Villarroel, Issa Diarra, Ousmane Koita, Pierre Gallian, and Xavier de Lamballerie
Author affiliations: Aix-Marseille Université-IRD 190-Inserm 1207, Marseille, France (L. Luciani, A. Amroun, A. Dubot-Pérès, P.M. Saba Villarroel, I. Diarra, P. Gallian, X. de Lamballerie); Sorbonne Université, Inserm, Saint-Antoine Hospital, Paris, France (N. Lapidus); Université de Corse Pascal Paoli, Corte, France (A. Falchi); Lao Red Cross, Vientiane, Laos (C. Souksakhone); Ministry of Health, Vientiane (M. Mayxay); University of Health Sciences, Vientiane (M. Mayxay); Mahosot Hospital, Vientiane (M. Mayxay, A. Dubot Pérès); University of Oxford, Oxford, UK (M. Mayxay, A. Dubot Pérès); University of Sciences, Bamako, Mali (I. Diarra, O. Koita); Établissement Français du Sang, La Plaine Saint Denis, France (P. Gallian)

Main Article

Table 1

Demographic characteristics of participants and results of vaccinia virus neutralization assay in study of orthopoxvirus seroprevalence and infection susceptibility in France, Bolivia, Laos, and Mali*

Characteristics France Bolivia Laos Mali
Total no. participants 4,876 601 657 255
M/F ratio 1.12 1.37 1.72 1.02
Mean year of birth ±SD 1967 ±14 1989 ±10 1985 ±9 1980 ±14
No. born before 1960 1,560 (32) 3 (0.5) 5 (0.8) 26 (10)
No. born before 1980
 3,826 (78)
 161 (27)
 171 (26)
 112 (43)
Antibody titers†
<20 4,137 (84.84) 598 (99.50) 632 (96.19) 211 (82.74)
20 425 (8.72) 1 (0.17) 22 (3.35) 30 (11.76)
40 217 (4.45) 1 (0.17) 3 (0.46) 12 (4.71)
80 86 (1.76) 1 (0.17) 0 (0) 2 (0.78)
160
 11 (0.23)
 0 (0)
 0 (0)
 0 (0)
Titer >40, % 6.44 0.33 0.46 5.49
Titer >20, % 15.16 0.50 3.81 17.25

*Values are no. (%) unless otherwise noted. Percentages were calculated according to the total number of study participants in each population. †No. (%) participants with different levels of neutralizing antibodies against vaccinia virus determined by seroneutralization assay.

Main Article

Page created: October 14, 2022
Page updated: November 21, 2022
Page reviewed: November 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external